Project Details
| Status | Active |
|---|---|
| Effective start/end date | 5/11/18 → 6/1/25 |
Funding
- Novartis Pharmaceuticals Corporation
SEG101B2201: A phase 2, Multicenter, Open-Label Study to AssessAppropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle
- Thompson, Alexis A (PD/PI)
Project: Research project